Eric K. Lei

Eric K. Lei

Auto-generated profile, based on publicly available information

Eric K. Lei

Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
EAEric N. Aguilar
Eric N. Aguilar
SSSatish Sagar
Satish Sagar
BMBrandy R. Murray
Brandy R. Murray
CRChristabelle Rajesh
Christabelle Rajesh
ELEric K. Lei
Eric K. Lei
PRPrakash Radhakrishnan
Prakash Radhakrishnan
Mucin-16 (MUC16) is a target for antibody-mediated immunotherapy in pancreatic ductal adenocarcinoma (PDAC) among other malignancies. The MUC16-specific monoclonal antibody AR9.6 has shown promise for PDAC immunotherapy and imaging. Here, we report the structural and biological characterization of the humanized AR9.6 antibody (huAR9.6). The structure of huAR9.6 was determined in complex with a MUC16 SEA (Sea urchin sperm, Enterokinase, Agrin) domain. Binding of huAR9.6 to recombinant, shed, and cell-surface MUC16 was characterized, and anti-PDAC activity was evaluated in vitro and in vivo. HuAR9.6 bound a discontinuous, SEA domain epitope with an overall affinity of 88 nmol/L. Binding affinity depended on the specific SEA domain(s) present, and glycosylation modestly enhanced affinity driven by favorable entropy and enthalpy and via distinct transition state thermodynamic pathways. Treatment with huAR9.6 reduced the in vitro growth, migration, invasion, and clonogenicity of MUC16-positive PDAC cells and patient-derived organoids (PDO). HuAR9.6 blocked MUC16-mediated ErbB and AKT activation in PDAC cells, PDOs, and patient-derived xenografts and induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. More importantly, huAR9.6 treatment caused substantial PDAC regression in subcutaneous and orthotopic tumor models. The mechanism of action of huAR9.6 may depend on dense avid binding to homologous SEA domains on MUC16. The results of this study validate the translational therapeutic potential of huAR9.6 against MUC16-positive PDACs.

17 June 2026
Verified
Other
Open access
PDF file
EAEric N. Aguilar
Eric N. Aguilar
SSSatish Sagar
Satish Sagar
BMBrandy R. Murray
Brandy R. Murray
CRChristabelle Rajesh
Christabelle Rajesh
ELEric K. Lei
Eric K. Lei
PRPrakash Radhakrishnan
Prakash Radhakrishnan
Fig. S2. Representative deuterium uptake plots of SEA5 regions with significantly reduced deuteration owing to interaction with mAR9.6 and huAR9.6

17 June 2026
Verified
Other
Open access
PDF file
EAEric N. Aguilar
Eric N. Aguilar
SSSatish Sagar
Satish Sagar
BMBrandy R. Murray
Brandy R. Murray
CRChristabelle Rajesh
Christabelle Rajesh
ELEric K. Lei
Eric K. Lei
PRPrakash Radhakrishnan
Prakash Radhakrishnan
Fig. S10. Conservation of AR9.6 epitope in homologous SEA domains. The epitope deduced from the X-ray structure of AR9.6 in complex with SEA5 (yellow ribbon diagram) occurs in 3 regions of the protein (shown in orange). (A) Alignment of SEA5 with homologous MUC16 SEA domains reveals that the epitope is well conserved among SEA domains 3-13, (B) less well conserved in SEA domains 1-2 (C), and the least conserved in SEA domains 13,14,16. (D) No significant epitope conservation occurs in SEA domain 15.

17 June 2026
Verified
Other
Open access
EAEric N. Aguilar
Eric N. Aguilar
SSSatish Sagar
Satish Sagar
BMBrandy R. Murray
Brandy R. Murray
CRChristabelle Rajesh
Christabelle Rajesh
ELEric K. Lei
Eric K. Lei
PRPrakash Radhakrishnan
Prakash Radhakrishnan
Fig. S3. MUC16 expression in PDAC cells and PDAC patients’ samples using huAR9.6 mAb. (A) Western blotting for MUC16 (with huAR9.6) in normal HPDE cells and AsPC-1, T3M4, Capan-2, Panc-1, MiaPaCa-2, Capan-1, BxPC-3, S2-013, FG and SU86.86 PDAC cells. Loading control: α-tubulin. (B) Immunofluorescent staining for MUC16 (AF647-huAR9.6, red) and α-tubulin (AF488, green) in T3M4-WT and T3M4-MUC16KO cells. (C) Representative image of immunofluorescent staining for MUC16 (AF647-huAR9.6, red) in normal pancreas (n=7) and PDAC tissue (n=32) obtained from the Rapid Autopsy Program at UNMC. (D) Representative images of immunohistochemistry for MUC16 on a patient-derived xenograft (PDX) microarray using huAR9.6; (E) Graphical representation of varying histoscores; (F) Graphical representation of consistency between histoscore (huAR9.6-based MUC16 detection) and RNA sequencing of MUC16 gene expression in PDX microarray samples (n = 31). (G) Western blotting for MUC16 (with huAR9.6) in ascites fluids (n = 34) obtained from PDAC patients via the Rapid Autopsy Program at UNMC. Western blot of N-glycanase, O-glycanase and sialidase treated (H) T3M4 cell lysates and (I) MUC16 TR1.2 glycopeptides probed with huAR9.6 mAb. Detection of α-tubulin served as the loading control.


4 June 2024
Verified
Other
Open access
PDF file
EAEric N. Aguilar
Eric N. Aguilar
SSSatish Sagar
Satish Sagar
BMBrandy R. Murray
Brandy R. Murray
CRChristabelle Rajesh
Christabelle Rajesh
ELEric K. Lei
Eric K. Lei
PRPrakash Radhakrishnan
Prakash Radhakrishnan
Fig. S4. huAR9.6 effects on PDAC cells and PDXs. Representative wound healing assay of vehicle (PBS), isotype control huIgG (40 µg/mL) and huAR9.6 (40 µg/mL) treated (A) T3M4 and (B) Capan-1 cells. (C) Schematic of patient-derived xenograft (PDX) derived cells obtained from primary human PDAC and liver metastasis. (D) Flow cytometric assessment of apoptosis using the Annexin-V/PI assay in T3M4 and Capan-1 cells treated with vehicle (PBS), isotype control huIgG (40 µg/mL) and huAR9.6 (40 µg/mL). Mean ± SD (n=3), p < 0.05 was considered as statistically significant using one-way ANOVA with Tukey’s multiple comparisons.